Physician profile
Matthew Laton
NPI 1487147435
$203.75
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.65 · 2022: $149.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.10 | 2021-2022 | |
| Esperion Therapeutics, INC. | $35.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.04 | 2022 | |
| Glaxosmithkline, LLC. | $25.26 | 2022 | |
| Amgen INC. | $22.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.46 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2022 | |
| Inogen, INC. | $12.64 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Laton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.